Serodus granted patent in Japan for product candidate within acute myocardial infarction

Oslo, June 23, 2015: Serodus ASA (Oslo Axess: SER), a Norwegian biotech company, today announced that the Japanese Patent Office has granted to Serodus Patent No. 5750373 titled, “IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases”.

The patent covers methods for treating various diseases caused by inflammation. This patent has already been issued to Serodus in United States, New Zealand and Russia and is currently pending in several other jurisdictions.

“Pre-clinical studies have demonstrated that SER130 is safe and well tolerated, and we will advance SER130 into the next development steps” stated Serodus’ CEO Eva Steiness.


For more information please contact:

Tore Kvam, CFO

Serodus ASA

Mobile: +47 959 34 199


Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see